Multicenter retrospective observational study on the clinical effectiveness of butyrate-producing Clostridium butyricum containing probiotics in patients with COVID-19

Morikawa et al., Virulence, doi:10.1080/21505594.2026.2673650, May 2026

Probiotics for COVID-19

19th treatment shown to reduce risk in March 2021, now with p = 0.00000044 from 29 studies.

No treatment is 100% effective.
Protocols combine treatments.

Retrospective 283 hospitalized COVID-19 patients in Japan showing potential benefit with butyrate-producing Clostridium butyricum (CB)-containing probiotic preparations, however this study has a number of significant issues:
Unreproducible headline p-value: the only significant result - mechanical ventilation duration (1.1 vs 3.9 days, p=0.0010) - cannot be reproduced from the reported numbers. A standard pooled t-test gives p≈0.125 and a Welch t-test gives p≈0.0003. The data are also too right-skewed (SD of 9.4 on a mean of 3.9, bounded at zero) for a parametric mean comparison to be valid - a nonparametric test is needed.
Pooled result contradict the subgroups: the CB group is just MIYA-BM (n=17) plus BIO-THREE (n=10). Under the same test, each subgroup's ventilation comparison is non-significant (p=0.64 and p=0.33), yet the combined group is reported at p=0.0010. A pooled group cannot be hundreds of times more significant than either half, indicating an internal inconsistency or error.
Unaddressed confounding by indication: CB preparations were given to only 9.5% of patients by non-randomized clinician choice, typically started days after admission. Patients stable enough to be started on an adjunctive probiotic differ systematically from those who deteriorate or die early, indicating healthy-user and immortal-time bias. No multivariable adjustment, propensity matching, or landmark analysis was done, and all comparisons are unadjusted.
Inappropriate categorical tests and a text/table mismatch: mortality and pneumonia were compared with uncorrected chi-square on very small cells (e.g., 1/27, 0/10) where Fisher's exact is standard. BIO-THREE mortality is also reported as p=0.1751 in the text but p=0.1815 in Table 6, with 0.1815 being the correct value.
Omitted safety signal: independent whole-genome-sequencing work shows that probiotic-derived C. butyricum (including MIYA-BM) can cause bacteremia in immunocompromised inpatients - the same drug and patient population. A paper advocating its use as a COVID-19 adjunct should address this risk.
Probiotic efficacy depends on the specific strains used. Specific microbes may decrease or increase COVID-19 risk1.
This study is excluded in meta-analysis: immortal-time bias may significantly affect results; healthy-user bias may significantly affect results; substantial unadjusted confounding by indication likely; data issues pending author response.
Morikawa et al., 17 May 2026, retrospective, Japan, peer-reviewed, 9 authors, study period August 2020 - June 2021. Contact: hkato59@med.mie-u.ac.jp.
Abstract: al O Taylor & Francis es G ta G CrossMark Virulence ISSN: 2150-5594 (Print) 2150-5608 (Online) Journal homepage: www.tandfonline.com/journals/kvir20 Multicenter retrospective observational study on the clinical effectiveness of butyrate-producing Clostridium butyricum containing probiotics in patients with COVID-19 Yoshihiko Morikawa, Hideo Kato, Takumi Umemura, Jun Hirai, Yuichi Shibata, Mao Hagihara, Nobuhiro Asai, Hiroshige Mikamo & Takuya Iwamoto To cite this article: Yoshihiko Morikawa, Hideo Kato, Takumi Umemura, Jun Hirai, Yuichi Shibata, Mao Hagihara, Nobuhiro Asai, Hiroshige Mikamo & Takuya Iwamoto (2026) Multicenter retrospective observational study on the clinical effectiveness of butyrateproducing Clostridium butyricum containing probiotics in patients with COVID-19, Virulence, 17:1, 2673650, DOI: 10.1080/21505594.2026.2673650 To link to this article: https://doi.org/10.1080/21505594.2026.2673650 © 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Published online: 17 May 2026. Submit your article to this journal Article views: 661 View related articles View Crossmark data HOST RESPONSE Multicenter retrospective observational study on the clinical effectiveness of butyrate-producing Clostridium butyricum containing probiotics in patients with COVID-19 Yoshihiko Morikawa a , Hideo Kato a,b , Takumi Umemura c , Jun Hirai d , Yuichi Shibata b , Mao Hagihara b,e , Nobuhiro Asai b , Hiroshige Mikamo b , and Takuya Iwamoto a,e a Department of Pharmacy, Mie University Hospital, Mie, Japan; b Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Japan; c Department of Pharmacy, Tosei General Hospital, Seto, Japan; d Division of Infection Control and Prevention, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; e Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University, Nagakute, Japan ABSTRACT Butyrate-producing bacteria, which are components of the gut microbiome, activate host defense mechanisms against several types of infections, including respiratory viral infections. However, the clinical effectiveness of butyrate-producing Clostridium butyricum (CB)-containing probiotics in patients with coronavirus disease 2019 (COVID-19) remains unclear. We investigated the inhospital mortality, period of mechanical ventilation, and incidence of secondary bacterial pneumonia in patients with COVID-19 from 2020 to 2021. The patients were divided into the probiotic (27) and non-probiotic (256) groups. The two groups did not show a significant difference in the SOFA scores (probiotic vs. non-probiotic, 2.1 ± 2.3 vs. 2.1 ± 2.9). Additionally, all patients received antiviral agents to treat COVID-19; however, the two groups did not show significant difference in their distribution. However, patients receiving CB preparations showed the shorter periods of mechanical ventilation (1.1 ± 2.5 days vs. 3.9 ± 9.4 days). Although not statistically significant, they also showed lower incidence of secondary bacterial pneumonia (7.4% vs. 15.6%) and the lower inhospital mortality (3.7% vs. 15.2%) compared to the non-probiotic group. This retrospective clinical study revealed that the administrations of CB preparations might attenuate clinical symptoms related to COVID-19 and improve mortality. However, further..
DOI record: { "DOI": "10.1080/21505594.2026.2673650", "ISSN": [ "2150-5594", "2150-5608" ], "URL": "http://dx.doi.org/10.1080/21505594.2026.2673650", "alternative-id": [ "10.1080/21505594.2026.2673650" ], "article-number": "2673650", "assertion": [ { "label": "Peer Review Statement", "name": "peerreview_statement", "order": 1, "value": "The publishing and review policy for this title is described in its Aims & Scope." }, { "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=kvir20", "label": "Aim & Scope", "name": "aims_and_scope_url", "order": 2, "value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=kvir20" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "order": 0, "value": "2025-04-30" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Revised", "name": "revised", "order": 1, "value": "2025-11-12" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "2026-05-09" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 3, "value": "2026-05-17" } ], "author": [ { "affiliation": [ { "name": "Mie University Hospital", "place": [ "Mie, Japan" ] } ], "family": "Morikawa", "given": "Yoshihiko", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "first" }, { "ORCID": "https://orcid.org/0000-0002-5272-9560", "affiliation": [ { "name": "Mie University Hospital", "place": [ "Mie, Japan" ] }, { "name": "Aichi Medical University", "place": [ "Nagakute, Japan" ] } ], "authenticated-orcid": false, "family": "Kato", "given": "Hideo", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [ { "name": "Tosei General Hospital", "place": [ "Seto, Japan" ] } ], "family": "Umemura", "given": "Takumi", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [ { "name": "Nippon Medical School Chiba Hokusoh Hospital", "place": [ "Chiba, Japan" ] } ], "family": "Hirai", "given": "Jun", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [ { "name": "Aichi Medical University", "place": [ "Nagakute, Japan" ] } ], "family": "Shibata", "given": "Yuichi", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [ { "name": "Aichi Medical University", "place": [ "Nagakute, Japan" ] }, { "name": "Aichi Medical University", "place": [ "Nagakute, Japan" ] } ], "family": "Hagihara", "given": "Mao", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [ { "name": "Aichi Medical University", "place": [ "Nagakute, Japan" ] } ], "family": "Asai", "given": "Nobuhiro", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [ { "name": "Aichi Medical University", "place": [ "Nagakute, Japan" ] } ], "family": "Mikamo", "given": "Hiroshige", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [ { "name": "Mie University Hospital", "place": [ "Mie, Japan" ] }, { "name": "Aichi Medical University", "place": [ "Nagakute, Japan" ] } ], "family": "Iwamoto", "given": "Takuya", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" } ], "container-title": "Virulence", "container-title-short": "Virulence", "content-domain": { "crossmark-restriction": true, "domain": [ "www.tandfonline.com" ] }, "created": { "date-parts": [ [ 2026, 5, 13 ] ], "date-time": "2026-05-13T17:25:30Z", "timestamp": 1778693130000 }, "deposited": { "date-parts": [ [ 2026, 5, 17 ] ], "date-time": "2026-05-17T15:36:33Z", "timestamp": 1779032193000 }, "indexed": { "date-parts": [ [ 2026, 5, 17 ] ], "date-time": "2026-05-17T16:07:10Z", "timestamp": 1779034030200, "version": "3.51.4" }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2026, 5, 17 ] ] }, "journal-issue": { "issue": "1", "published-print": { "date-parts": [ [ 2026, 12, 31 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 5, 17 ] ], "date-time": "2026-05-17T00:00:00Z", "timestamp": 1778976000000 } } ], "link": [ { "URL": "https://www.tandfonline.com/doi/pdf/10.1080/21505594.2026.2673650", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "301", "original-title": [], "prefix": "10.1080", "published": { "date-parts": [ [ 2026, 5, 17 ] ] }, "published-online": { "date-parts": [ [ 2026, 5, 17 ] ] }, "published-print": { "date-parts": [ [ 2026, 12, 31 ] ] }, "publisher": "Informa UK Limited", "reference": [ { "key": "e_1_3_6_2_1", "unstructured": "World Health Organization. Coronavirus disease 2019. (COVID-19) situation report. [cited 2024 Oct 27]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports" }, { "key": "e_1_3_6_3_1", "unstructured": "WHO. Therapeutics and COVID-19: living guidance. 2023 [cited 2025 Jan 8]. Available from: http://iris.who.int/bitstream/handle/10665/362843/WHO-2019-nCov-therapeutics-2022.5-eng.pdf" }, { "key": "e_1_3_6_4_1", "unstructured": "Our world in date. COVID-19 vaccinations. 2023 [cited 2025 Jan 8]. Available from: http://ourworldindata.org/covid-vaccinations" }, { "DOI": "10.1038/d41586-021-02532-4", "doi-asserted-by": "publisher", "key": "e_1_3_6_5_1" }, { "article-title": "Probiotics as promising immunomodulatory agents to prevent COVID-19 infection: a narrative review", "author": "Adnan ML", "first-page": "121", "issue": "2", "journal-title": "Int J Med Students", "key": "e_1_3_6_6_1", "unstructured": "Adnan ML, Pramaningtyas MD. Probiotics as promising immunomodulatory agents to prevent COVID-19 infection: a narrative review. Int J Med Students. 2020;8(2):121–125.", "volume": "8", "year": "2020" }, { "DOI": "10.1016/j.synbio.2018.03.001", "doi-asserted-by": "publisher", "key": "e_1_3_6_7_1" }, { "DOI": "10.1016/j.intimp.2024.112169", "doi-asserted-by": "publisher", "key": "e_1_3_6_8_1" }, { "DOI": "10.3934/microbiol.2022024", "doi-asserted-by": "publisher", "key": "e_1_3_6_9_1" }, { "DOI": "10.1017/S0007114514000075", "doi-asserted-by": "publisher", "key": "e_1_3_6_10_1" }, { "DOI": "10.1128/JVI.00326-20", "doi-asserted-by": "publisher", "key": "e_1_3_6_11_1" }, { "DOI": "10.1161/HYPERTENSIONAHA.120.16647", "doi-asserted-by": "publisher", "key": "e_1_3_6_12_1" }, { "DOI": "10.3390/molecules27030862", "doi-asserted-by": "publisher", "key": "e_1_3_6_13_1" }, { "DOI": "10.1016/j.eng.2020.05.013", "doi-asserted-by": "publisher", "key": "e_1_3_6_14_1" }, { "DOI": "10.1053/j.gastro.2020.05.048", "doi-asserted-by": "publisher", "key": "e_1_3_6_15_1" }, { "DOI": "10.1016/j.cmi.2015.10.014", "doi-asserted-by": "publisher", "key": "e_1_3_6_16_1" }, { "DOI": "10.1086/591708", "doi-asserted-by": "publisher", "key": "e_1_3_6_17_1" }, { "DOI": "10.3390/nu14071478", "doi-asserted-by": "publisher", "key": "e_1_3_6_18_1" }, { "DOI": "10.1016/j.immuni.2018.04.022", "doi-asserted-by": "publisher", "key": "e_1_3_6_19_1" }, { "DOI": "10.5056/jnm20149", "doi-asserted-by": "publisher", "key": "e_1_3_6_20_1" }, { "DOI": "10.1111/febs.16945", "doi-asserted-by": "publisher", "key": "e_1_3_6_21_1" }, { "DOI": "10.1038/nature12721", "doi-asserted-by": "publisher", "key": "e_1_3_6_22_1" }, { "DOI": "10.1136/gutjnl-2020-322599", "doi-asserted-by": "publisher", "key": "e_1_3_6_23_1" }, { "DOI": "10.1016/j.celrep.2020.02.013", "doi-asserted-by": "publisher", "key": "e_1_3_6_24_1" }, { "DOI": "10.1182/blood-2018-01-828996", "doi-asserted-by": "publisher", "key": "e_1_3_6_25_1" }, { "DOI": "10.1016/j.celrep.2022.111755", "doi-asserted-by": "publisher", "key": "e_1_3_6_26_1" }, { "DOI": "10.1186/s13054-020-03006-1", "doi-asserted-by": "publisher", "key": "e_1_3_6_27_1" }, { "DOI": "10.3389/fnut.2021.772033", "doi-asserted-by": "publisher", "key": "e_1_3_6_28_1" }, { "DOI": "10.1186/s12934-019-1085-1", "doi-asserted-by": "publisher", "key": "e_1_3_6_29_1" }, { "article-title": "Stimulation of bacterial growth of some strains of bifidobaclerium by a crude preparation of metabolites from Bacillus mesentericus TO-A", "author": "Lino H", "first-page": "73", "journal-title": "Biomed Lett", "key": "e_1_3_6_30_1", "unstructured": "Lino H, Fukaya K ,Hirasawa Y, et al. Stimulation of bacterial growth of some strains of bifidobaclerium by a crude preparation of metabolites from Bacillus mesentericus TO-A. Biomed Lett. 1993;48: 73–78.https://eurekamag.com/research/009/458/009458208.php?srsltid=AfmBOoq_b1sf2XLXRea6qE7Q-ERnaAPyfJ5G-tT5vorRweyqxFnNZ4Vj.", "volume": "48", "year": "1993" }, { "DOI": "10.1371/journal.pgen.1010391", "doi-asserted-by": "publisher", "key": "e_1_3_6_31_1" }, { "key": "e_1_3_6_32_1", "unstructured": "WHO. SARS-CoV-2 variant risk evaluation framework. 2023 [cited 2024 Oct 27]. Available from: https://iris.who.int/bitstream/handle/10665/372693/WHO-2019-nCoV-Variants-Risk_assessment-2023.1-eng.pdf?sequence=1" } ], "reference-count": 31, "references-count": 31, "relation": {}, "resource": { "primary": { "URL": "https://www.tandfonline.com/doi/full/10.1080/21505594.2026.2673650" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Multicenter retrospective observational study on the clinical effectiveness of butyrate-producing\n <i>Clostridium butyricum</i>\n containing probiotics in patients with COVID-19", "type": "journal-article", "update-policy": "https://doi.org/10.1080/tandf_crossmark_01", "volume": "17" }
Late treatment
is less effective